orexo_logo

AstraZeneca buys rights to Orexo respiratory programme

pharmafile | March 21, 2016 | News story | Sales and Marketing |  AstraZeneca, COPD, asthma, orexo 

AstraZeneca has bought the rights to a respiratory programme from Sweden’s Orexo for $5 million.

The deal centres on the rights to Orexo’s candidate OX-CLI, which treats conditions like asthma and COPD.

With the acquisition, AstraZeneca takes up an option established in 2013, when the companies signed a deal allowing AstraZeneca to conduct research and evaluation of compounds in the OX-CLI programme, and giving it the option of a full asset transfer.  

Advertisement

Nikolaj Sørensen, chief executive of Orexo, says: “I am pleased that AstraZeneca has decided to exercise the company’s option to acquire this novel and innovative program. It is an important sign of confidence in OX-CLI, from one of the leading companies within respiratory diseases. We look forward to follow the continued product development of OX-CLI, which we believe has the potential to become an important new medication in the treatment of respiratory diseases.

“Pushing the boundaries of science to transform disease management and improve asthma patient outcomes is central to our respiratory strategy, and the OX-CLI compounds could enable us to offer a completely new personalised treatment for patients whose condition is caused by the dysregulation of leukotrienes. I am particularly pleased to see this new collaboration come to fruition as it could help to further strengthen the Nordic Life Science eco-system,” adds Maarten Kraan, vice president, RIA Innovative Medicines unit, AstraZeneca.

Joel Levy

Related Content

How will biomarker-led diagnostics reshape respiratory medicine?

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

Five Facts about COPD

1 Chronic obstructive pulmonary disease is a group of progressive lung conditions, principally emphysema and …

AstraZeneca’s Trixeo approved in EU for asthma

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

The Gateway to Local Adoption Series

Latest content




Five Facts about COPD

October 11, 2026